Steve Krognes Biography and Net Worth

Director of Guardant Health

Steve Krognes has served as a member of Guardant Health’s Board of Directors since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was Chief Financial Officer at Denali Therapeutics Inc. from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche Holding AG. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway.

Mr. Krognes currently serves as a member of the Board of Directors at Denali Therapeutics Inc., Gritstone bio, Inc., argenx SE and ClavystBio, and previously served on the Board of Directors at Corvus Pharmaceuticals, Inc. from January 2016 to March 2021 and RLS Global AB from January 2016 to January 2023. He received a Master of Business Administration degree from Harvard Business School and a Bachelor of Science degree in economics from The Wharton School of the University of Pennsylvania.

What is Steve E. Krognes' net worth?: The estimated net worth of Steve E. Krognes is at least $1.31 million as of June 4th, 2026. Mr. Krognes owns 10,222 shares of Guardant Health stock worth more than $1,305,125 as of June 8th. This net worth estimate does not reflect any other investments that Mr. Krognes may own. Learn More about Steve E. Krognes' net worth.
How do I contact Steve E. Krognes?: The corporate mailing address for Mr. Krognes and other Guardant Health executives is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. Guardant Health can also be reached via phone at (855) 698-8887 and via email at [email protected]. Learn More on Steve E. Krognes' contact information.
Has Steve E. Krognes been buying or selling shares of Guardant Health?: In the last ninety days, Steve E. Krognes has sold $1,231,547.94 in Guardant Health stock. Most recently, Steve E. Krognes sold 9,294 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $132.51, for a transaction totalling $1,231,547.94. Following the completion of the sale, the director now directly owns 10,222 shares of the company's stock, valued at $1,354,517.22. Learn More on Steve E. Krognes' trading history.
Who are Guardant Health's active insiders?: Guardant Health's insider roster includes Michael Bell (CFO), Derek Bertocci (CFO), Darya Chudova (CTO), Ian Clark (Director), Helmy Eltoukhy (CEO), Chris Freeman (Chief Commercial Officer, Oncology), Medina Hidalgo (Director), Meghan Joyce (Director), Kumud Kalia (Insider), Samir Kaul (Director), Steve Krognes (Director), Stanley Meresman (Director), Amelia Merrill (SVP), Terilyn Monroe (Insider), Myrtle Potter (Director), John Saia (Insider), Amirali Talasaz (COO), and Musa Tariq (Director). Learn More on Guardant Health's active insiders.
Are insiders buying or selling shares of Guardant Health?: During the last year, insiders at the sold shares 50 times. They sold a total of 1,293,221 shares worth more than $113,008,313.91. The most recent insider tranaction occured on June, 4th when Director Steve E Krognes sold 9,294 shares worth more than $1,231,547.94. Insiders at Guardant Health own 5.6% of the company. Learn More about insider trades at Guardant Health.
Information on this page was last updated on 6/4/2026.

Steve E. Krognes Insider Trading History at Guardant Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2026	Sell	9,294	$132.51	$1,231,547.94	10,222

Steve E. Krognes Buying and Selling Activity at Guardant Health

Guardant Health Company Overview

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $125.95

$126.51

$132.00

50 Day Range

MA: $99.39

$78.60

$133.22

2 Week Range

Now: $125.95

$40.35

$134.28

Volume

1,138,072 shs

Average Volume

2,127,158 shs

Market Capitalization

$16.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61